Table 1

Baseline demographic and clinical characteristics of the patients with and without subclinical inflammation

Sonographic inflammation (n=96)No sonographic inflammation (n=26)p-Value
Age, years (SD)59.06±10.7957.53±8.830.509
Gender (female, %)76 (79.2)22 (84.6%)0.378
Body mass index (kg/m2)22.54±3.3123.73±4.760.144
ANA (n, %)34 (35.4)6 (23.1%)0.346
RF (n, %)80 (83.3)21 (80.8%)0.479
ACPA (n, %)79 (82.6)22 (83.1%)0.577
DAS28 score before starting anti-TNF therapy6.62±0.476.84±0.400.035
DAS28 score before tapering anti-TNF therapy2.51±0.362.55±0.340.645
Methotrexate (n, %)70 (72.9)26 (27.1%)0.445
Hydroxychloroquine (n, %)84 (87.5)21 (80.8%)0.357
Sulphasalazine (n, %)17 (17.7)2 (7.7%)0.174
Leflunomide (n, %)2 (2.1)2 (7.4%)0.199
Ciclosporin (n, %)2 (2.1)0 (0%)0.618
Anti-TNF tapering (moderate tapering, %)66 (68.8)10 (38.5%)0.005
  • ACPA, anticitrullinated protein antibodies; ANA, antinuclear antibody; RF, rheumatoid factor; DAS28, 28-joint Disease Activity Score; TNF, tumor necrosis factor.